Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report

Cancer Immunology, Immunotherapy

Volumn 67, Issue 4, 2018, Pages 563-573

  McGuire, Helen M ^a   Shklovskaya, Elena ^a,b   Edwards, Jarem ^a   Trevillian, Paul R ^c   McCaughan, Geoffrey W ^d   Bertolino, Patrick ^d   McKenzie, Catriona ^e   Gourlay, Ralph ^f   Gallagher, Stuart J ^a   Fazekas de St Groth, Barbara ^a   Hersey, Peter ^a,d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b MACQUARIE UNIVERSITY   (Australia)

^c JOHN HUNTER HOSPITAL   (Australia)

^d CENTENARY INSTITUTE   (Australia)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^f UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Anti PD 1 therapy; Corticosteroids; Hepatitis; Immune related adverse events; Melanoma; T cell

Indexed keywords

ALANINE AMINOTRANSFERASE; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR3; DEXAMETHASONE; MEPREDNISONE; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID; PEMBROLIZUMAB; PREDNISONE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; THYMOCYTE ANTIBODY; CORTICOSTEROID; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURGERY; CASE REPORT; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG DOSE INCREASE; DRUG RESISTANCE; FEMALE; HEPATITIS; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; MASS CYTOMETRY; MELANOMA; MIDDLE AGED; NEUTROPHIL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH1 CELL; TH17 CELL; AGED; ANTAGONISTS AND INHIBITORS; CASE CONTROL STUDY; DRUG EFFECT; IMMUNOLOGY; IMMUNOTHERAPY; MALE; METABOLISM; PATHOLOGY; PROGNOSIS; T LYMPHOCYTE;

ADRENAL CORTEX HORMONES; AGED; ANTIBODIES, MONOCLONAL; CASE-CONTROL STUDIES; DRUG RESISTANCE, NEOPLASM; FEMALE; HEPATITIS; HUMANS; IMMUNOTHERAPY; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES;

EID: 85039753655     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-017-2107-7     Document Type: Article

References (39)

1. Hersey P, Gowrishankar K (2015) Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma. Future Oncol 11(1):133–140. https://doi.org/10.2217/fon.14.205
2. Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16(4):375–384. https://doi.org/10.1016/S1470-2045(15)70076-8
3. Ugurel S, Rohmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Long GV, Lorigan P, McArthur GA, Ribas A, Robert C, Schadendorf D, Garbe C (2016) Survival of patients with advanced metastatic melanoma: the impact of novel therapies. Eur J Cancer 53:125–134. https://doi.org/10.1016/j.ejca.2015.09.013
4. Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, Gangadhar TC, Hersey P, Dronca R, Joseph RW, Zarour H, Chmielowski B, Lawrence DP, Algazi A, Rizvi NA, Hoffner B, Mateus C, Gergich K, Lindia JA, Giannotti M, Li XN, Ebbinghaus S, Kang SP, Robert C (2016) Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 315(15):1600–1609. https://doi.org/10.1001/jama.2016.4059
5. Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor DR, Salama AK, Taylor MH, Ott PA, Horak C, Gagnier P, Jiang J, Wolchok JD, Postow MA (2016) Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 17(11):1558–1568. https://doi.org/10.1016/S1470-2045(16)30366-7
6. Gandini S, Massi D, Mandala M (2016) PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: a systematic review and meta-analysis. Crit Rev Oncol Hematol 100:88–98. https://doi.org/10.1016/j.critrevonc.2016.02.001
7. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 372(4):311–319. https://doi.org/10.1056/NEJMoa1411087
8. Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, Schmidgen MI, Gutzmer R, Utikal JS, Goppner D, Hassel JC, Meier F, Tietze JK, Thomas I, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM (2016) Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 60:190–209. https://doi.org/10.1016/j.ejca.2016.02.025
9. Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I, Schmidgen MI, Gutzmer R, Utikal JS, Goppner D, Hassel JC, Meier F, Tietze JK, Forschner A, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM (2016) Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 60:210–225. https://doi.org/10.1016/j.ejca.2016.02.024
10. Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, Massard C, Fuerea A, Ribrag V, Gazzah A, Armand JP, Amellal N, Angevin E, Noel N, Boutros C, Mateus C, Robert C, Soria JC, Marabelle A, Lambotte O (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139–148. https://doi.org/10.1016/j.ejca.2015.11.016
11. Greenwald RJ, Freeman GJ, Sharpe AH (2005) The B7 family revisited. Annu Rev Immunol 23:515–548. https://doi.org/10.1146/annurev.immunol.23.021704.115611
12. Yao S, Zhu Y, Chen L (2013) Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov 12(2):130–146. https://doi.org/10.1038/nrd3877
13. Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677–704. https://doi.org/10.1146/annurev.immunol.26.021607.090331
14. Schildberg FA, Klein SR, Freeman GJ, Sharpe AH (2016) Coinhibitory pathways in the B7-CD28 ligand-receptor family. Immunity 44(5):955–972. https://doi.org/10.1016/j.immuni.2016.05.002
15. Hui E, Cheung J, Zhu J, Su X, Taylor MJ, Wallweber HA, Sasmal DK, Huang J, Kim JM, Mellman I, Vale RD (2017) T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science 355(6332):1428–1433. https://doi.org/10.1126/science.aaf1292
16. Kamphorst AO, Wieland A, Nasti T, Yang S, Zhang R, Barber DL, Konieczny BT, Daugherty CZ, Koenig L, Yu K, Sica GL, Sharpe AH, Freeman GJ, Blazar BR, Turka LA, Owonikoko TK, Pillai RN, Ramalingam SS, Araki K, Ahmed R (2017) Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science 355(6332):1423–1427. https://doi.org/10.1126/science.aaf0683
17. Cheng R, Cooper A, Kench J, Watson G, Bye W, McNeil C, Shackel N (2015) Ipilimumab-induced toxicities and the gastroenterologist. J Gastroenterol Hepatol 30(4):657–666. https://doi.org/10.1111/jgh.12888
18. Ramesh R, Kozhaya L, McKevitt K, Djuretic IM, Carlson TJ, Quintero MA, McCauley JL, Abreu MT, Unutmaz D, Sundrud MS (2014) Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J Exp Med 211(1):89–104. https://doi.org/10.1084/jem.20130301
19. Newell EW, Sigal N, Bendall SC, Nolan GP, Davis MM (2012) Cytometry by time-of-flight shows combinatorial cytokine expression and virus-specific cell niches within a continuum of CD8 + T cell phenotypes. Immunity 36(1):142–152. https://doi.org/10.1016/j.immuni.2012.01.002
20. Bendall SC, Simonds EF, Qiu P, Amir el AD, Krutzik PO, Finck R, Bruggner RV, Melamed R, Trejo A, Ornatsky OI, Balderas RS, Plevritis SK, Sachs K, Pe’er D, Tanner SD, Nolan GP (2011) Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science 332(6030):687–696. https://doi.org/10.1126/science.1198704
21. Dale DC, Fauci AS, Guerry DI, Wolff SM (1975) Comparison of agents producing a neutrophilic leukocytosis in man. Hydrocortisone, prednisone, endotoxin, and etiocholanolone. J Clin Invest 56(4):808–813. https://doi.org/10.1172/JCI108159
22. Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M, Lanzavecchia A, Sallusto F, Napolitani G (2007) Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 8(6):639–646. https://doi.org/10.1038/ni1467
23. Dong H, Zhu G, Tamada K, Flies DB, van Deursen JM, Chen L (2004) B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes. Immunity 20(3):327–336
24. International MHC, Network AG, Rioux JD, Goyette P, Vyse TJ, Hammarström L, Fernando MM, Green T, De Jager PL, Foisy S, Wang J, de Bakker PI, Leslie S, McVean G, Padyukov L, Alfredsson L, Annese V, Hafler DA, Pan-Hammarström Q, Matell R, Sawcer SJ, Compston AD, Cree BA, Mirel DB, Daly MJ, Behrens TW, Klareskog L, Gregersen PK, Oksenberg JR, Hauser SL (2009) Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. Proc Natl Acad Sci USA 106(44):18680–18685. https://doi.org/10.1073/pnas.0909307106
25. Fernando MM, Stevens CR, Walsh EC, De Jager PL, Goyette P, Plenge RM, Vyse TJ, Rioux JD (2008) Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Genet 4(4):e1000024. https://doi.org/10.1371/journal.pgen.1000024
26. Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, McQuade JL, Shoushtari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS, Davies MA, Sandhu SK, Long GV (2017) Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 28(2):368–376. https://doi.org/10.1093/annonc/mdw443
27. Lorigan P, Green AC (2017) Immunotherapy: Does adjuvant ipilimumab have little adverse effect on quality of life? Nat Rev Clin Oncol 14(7):395–396. https://doi.org/10.1038/nrclinonc.2017.60
28. Chmiel KD, Suan D, Liddle C, Nankivell B, Ibrahim R, Bautista C, Thompson J, Fulcher D, Kefford R (2011) Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol 29(9):e237–e240. https://doi.org/10.1200/JCO.2010.32.2206
29. Ahmed T, Pandey R, Shah B, Black J (2015) Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy. BMJ Case Rep. https://doi.org/10.1136/bcr-2014-208102
30. Buszko M, Jakic B, Ploner C, Hoertnagl P, Mayerl C, Wick G, Cappellano G (2017) In vitro immunoregulatory effects of thymoglobulin on human immune cell subpopulations. Immunol Lett 186:1–8. https://doi.org/10.1016/j.imlet.2017.04.002
31. Xiao X, Miao Q, Chang C, Gershwin ME, Ma X (2014) Common variable immunodeficiency and autoimmunity: an inconvenient truth. Autoimmun Rev 13(8):858–864. https://doi.org/10.1016/j.autrev.2014.04.006
32. Merayo-Chalico J, Rajme-Lopez S, Barrera-Vargas A, Alcocer-Varela J, Diaz-Zamudio M, Gomez-Martin D (2016) Lymphopenia and autoimmunity: a double-edged sword. Hum Immunol 77(10):921–929. https://doi.org/10.1016/j.humimm.2016.06.016
33. Hieshima K, Imai T, Opdenakker G, Van Damme J, Kusuda J, Tei H, Sakaki Y, Takatsuki K, Miura R, Yoshie O, Nomiyama H (1997) Molecular cloning of a novel human CC chemokine liver and activation-regulated chemokine (LARC) expressed in liver. Chemotactic activity for lymphocytes and gene localization on chromosome 2. J Biol Chem 272(9):5846–5853
34. Armada A, Martins C, Spengler G, Molnar J, Amaral L, Rodrigues AS, Viveiros M (2016) Fluorimetric methods for analysis of permeability, drug transport kinetics, and inhibition of the ABCB1 Membrane transporter. Methods Mol Biol 1395:87–103. https://doi.org/10.1007/978-1-4939-3347-1_7
35. Tabarkiewicz J, Pogoda K, Karczmarczyk A, Pozarowski P, Giannopoulos K (2015) The role of IL-17 and Th17 lymphocytes in autoimmune diseases. Arch Immunol Ther Exp (Warsz) 63(6):435–449. https://doi.org/10.1007/s00005-015-0344-z
36. Reis M, Ogonek J, Qesari M, Borges NM, Nicholson L, Preussner L, Dickinson AM, Wang XN, Weissinger EM, Richter A (2016) Recent developments in cellular immunotherapy for HSCT-associated complications. Front Immunol 7:500. https://doi.org/10.3389/fimmu.2016.00500
37. Conklin LS, Hanley PJ, Galipeau J, Barrett J, Bollard CM (2017) Intravenous mesenchymal stromal cell therapy for inflammatory bowel disease: lessons from the acute graft versus host disease experience. Cytotherapy 19(6):655–667. https://doi.org/10.1016/j.jcyt.2017.03.006
38. Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuk F, Ajib S, de Fontbrune FS, Na IK, Penter L, Holtick U, Wolf D, Schuler E, Meyer E, Apostolova P, Bertz H, Marks R, Lubbert M, Wasch R, Scheid C, Stolzel F, Ordemann R, Bug G, Kobbe G, Negrin R, Brune M, Spyridonidis A, Schmitt-Graff A, van der Velden W, Huls G, Mielke S, Grigoleit GU, Kuball J, Flynn R, Ihorst G, Du J, Blazar BR, Arnold R, Kroger N, Passweg J, Halter J, Socie G, Beelen D, Peschel C, Neubauer A, Finke J, Duyster J, von Bubnoff N (2015) Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia 29(10):2062–2068. https://doi.org/10.1038/leu.2015.212
39. Abraham C, Dulai PS, Vermeire S, Sandborn WJ (2017) Lessons learned from trials targeting cytokine pathways in patients with inflammatory bowel diseases. Gastroenterology 152(2):374–388.e374. https://doi.org/10.1053/j.gastro.2016.10.018